| ★ | How to Sequence Omalizumab, Dupilumab, and Remibrutinib in CSU | | 74 | Estados Unidos | |
| 17 | Augmented Collective Intelligence: The Real AI Future | | 1.7K | Estados Unidos | 63 |
| 12 | Diabetes Technology at a Turning Point: What’s New and What’s Next | | 581 | Estados Unidos | 64 |
| 9 | Trustworthy Agentic Commerce in a Hybrid Ecosystem | FinCloud Summit 2026 | Cloud Security Alliance (CSA) @cloudsecurityalliancedotorg | 303 | Estados Unidos | 64 |
| 7 | GP-SOD Plus Targeted Phototherapy Improves Vitiligo Repigmentation | | 249 | Estados Unidos | 64 |
| 2 | What Comes Next for PORT-77 as It Heads Toward Phase 2b/3? | | 196 | Estados Unidos | 70 |
| 18 | REACH Study: Broncho-Vaxom (OM-85) Cuts Recurrent Respiratory Tract Infections | | 134 | Estados Unidos | 63 |
| 13 | Valoración datos paro CEA: Andalucía lidera en mayo la caída del paro a nivel nacional | Confederación de Empresarios de Andalucía - CEA @ceaes | 118 | España | 63 |
| 11 | Guideline-Directed Care Improves Limb Outcomes in Peripheral Artery Disease | | 109 | Estados Unidos | 64 |
| 3 | Brensocatib, 1 Year Later: Who Benefits Most? | Mark Metersky, MD | | 98 | Estados Unidos | 67 |
| 16 | Prof. Ashutosh Mohan - Introduction | SWAYAM BHU @swayam-ini-bhu | 86 | — | 63 |
| 8 | Avapritinib's 4-Year Impact on Quality of Life in ISM | Thanai Pongdee, MD | | 73 | Estados Unidos | 64 |
| 4 | Addressing Advances and Roadblocks in Lipid Management, With Joseph Saseen, PharmD | | 64 | Estados Unidos | 66 |
| 1 | Can CSU Patients Achieve True Remission? BTK Inhibitors, Biomarker Barriers, & More | EAC 2026 | | 58 | Estados Unidos | 82 |
| 5 | How Well-Being in Psoriasis is Being Assessed Via WHO-5, With Ulrich Mrowietz, MD | | 56 | Estados Unidos | 65 |
| 6 | POCUS is Standard of Care in Critical Care, With Rhea Votipka, NP | | 35 | Estados Unidos | 65 |
| 10 | Increasing Guideline-Directed Care Adherence in Peripheral Artery Disease | | 31 | Estados Unidos | 64 |
| 19 | Addressing the Manifold Barriers in Hypertension, With Michael Miedema, MD | | 27 | Estados Unidos | 63 |
| 20 | BE HEARD EXT: Bimekizumab Shows Greater Benefit With Earlier Use in HS | | 14 | Estados Unidos | 63 |
| 15 | The Cost of Delay: How Prior Authorization Is Impacting Dermatology | | 12 | Estados Unidos | 63 |
| 14 | Entrevista a Eckenner Recalde. Asambleísta electo por Izquierda Democrática | tendencias. ec @tendenciasec | 8 | Ecuador | 63 |